Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742853 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
A Phase 1 study of Dyslipidemia, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
- 3
- Study locations
NCT06742853 is a Phase 1 study of Dyslipidemia that has completed, run by AstraZeneca. The registered enrollment target is 81 participants, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06742853, a Phase 1 study of Dyslipidemia, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD0780
- DRUG Rosuvastatin
- DRUG Bempedoic Acid
- DRUG Ezetimibe
Study Locations (3)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Other
- Research Site - Harrow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2025-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06742853
The ClinicalTrials.gov registry entry for NCT06742853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 40 other Dyslipidemia trials with a reported enrollment target (78% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemia appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT06742853 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT06742853 about?
NCT06742853 is a clinical study titled "A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.". The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
What is the current status of trial NCT06742853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2024-12-20. Estimated completion is 2025-10-29.
What conditions does trial NCT06742853 study?
This clinical trial studies the following conditions: Dyslipidemia.
What interventions are being tested in trial NCT06742853?
The interventions under investigation include: Placebo (DRUG), AZD0780 (DRUG), Rosuvastatin (DRUG), Bempedoic Acid (DRUG), Ezetimibe (DRUG).
Who is sponsoring clinical trial NCT06742853?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742853 being conducted?
This trial has 3 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
RECRUITING · Phase 1
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
COMPLETED · Phase 1
-
ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study
COMPLETED · Phase 1
-
Effects of Niacin On Fatty Acid Trapping
COMPLETED · Phase 1
-
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.